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Abstract
Activation of Hepatic stellate cells (HSC) in fibrogenesis involves distinct morphological and
biochemical changes. This activation requires the coordinated changes in activity of several
transcription factors. Peroxisome proliferator-activated receptor gamma (PPAR gamma) is one
such factor whose activity is decreased in activated HSC. PPAR gamma ligands suppress several
markers of HSC activation such as expression of collagen and alpha smooth muscle actin (alpha-
SMA), cell proliferation and migration. Expression of PPAR gamma, per se, also inhibits HSC
activation. These findings support the role of PPAR gamma in reversion of activated HSC toward
their quiescent state.
Introduction
Hepatic stellate cells (HSC) are vitamin A storing, perisi-
nusoidal pericytes that undergo phenotypic changes char-
acterized as "myofibroblastic activation" during liver
fibrogenesis. This activation process involves morpholog-
ical and biochemical changes. To understand the molecu-
lar basis of the activation, many laboratories have
characterized alterations in specific gene regulation and
intracellular signaling that may confer phenotypic
changes of activation. Depletion of retinoids is one of the
key features in HSC activation. The contents of all-trans
and 9-cis retinoic acids (biologically active metabolites of
vitamin A), are also decreased in activated HSC. RAR and
RXR, the nuclear receptors for these retinoic acids are also
reduced in activated HSC [1]. RXR heterodimerizes with
the members of the steroid/thyroid hormone receptor
superfamily, such as vitamin D receptor, peroxisome pro-
liferator-activated receptor (PPAR) and liver X receptor
(LXR). PPAR gamma is a ligand dependent transcription
factor that is predominantly expressed in adipose tissue
and plays an important role in adipogenesis, fat and
energy metabolism. There are at least three isoforms of
PPAR gamma (gamma 1, gamma 2, gamma 3). PPAR
gamma 2 is predominantly expressed in fat tissue while
PPAR gamma 1 is found in various organs including liver.
Activated PPAR gamma regulates transcription of several
genes after binding to a specific PPAR response element,
PPRE, a hexameric direct repeat (TGACCT) separated by a
single nucleotide. This article reviews the considerable
advances that have recently been made for the regulatory
role of PPAR gamma in activation of HSC.
Expression of PPAR Gamma in HSC
The transcription factors such as NF-kappa B, AP1 and
KRUPPEL like transcription factor are all associated with
the activated phenotype of HSC. However, the expression
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and activity of PPAR gamma are suppressed in activated
HSC. In fact, three independent studies demonstrated that
PPAR gamma activity was reduced in cultured activated
human and rat HSC [2-4]. Our in vivo studies [4] also
revealed a decrease in the expression of PPAR gamma in
HSC from a bile-duct ligated rat model (HSC-BDL) as
compared to HSC from sham operated normal rat (HSC-
sham) (Fig. 1).
To directly assess the binding of PPAR gamma to PPRE,
electrophoretic mobility shift assay (EMSA) was per-
formed using the ARE7 probe (a PPRE element of aP2
gene). PPRE binding of nuclear extracts from HSC-BDL
was decreased compared to that in HSC-sham. The specif-
icity of binding was supported by supershift assay using
anti-PPAR gamma antibodies. Interestingly, the treatment
of culture-activated HSC with a natural ligand for PPAR
gamma (15dPGJ2) caused reappearance of PPAR gamma
mRNA (Fig. 2).
Effects of PPAR Gamma Ligands on Activation 
Markers of HSC
To assess the relationship between PPAR gamma and acti-
vation of HSC, the effects of PPAR gamma ligands on HSC
activation markers have been addressed. Miyahara et. al
demonstrated that 15dPGJ2 and BRL49653 (rosiglita-
zone) suppressed DNA synthesis by 40–50% in cultured
activated HSC [4]. Galli et al. and Marra et al. also inde-
pendently showed that PDGF stimulated proliferation of
human HSC was inhibited by 15dPGJ2, ciglitazone and
troglitazone [2,3]. Collagen production, another funda-
mental parameter of HSC activation, was also inhibited
by 15dPGJ2 [4]. This inhibition was blocked with a PPAR
gamma antagonist (GW9662). Further, alpha-SMA
expression, PDGF induced HSC migration and cytokine
induced MCP-1 expression, other features of HSC activa-
tion, were also inhibited by thiazolinedione (TZD) and
15dPGJ2 [4]. Finally, the treatment with TZD was shown
to ameliorate liver fibrosis in both toxic and cholestatic
models [5]. All these findings support a notion that PPAR
gamma ligand treatment inhibits HSC activation and liver
fibrosis. However, a recent study by Chawla, et al., dem-
onstrated that so called "PPAR gamma ligands"(15dPGJ2
PPRE binding is diminished in HSC from BDL compared to  sham animals Figure 1
PPRE binding is diminished in HSC from BDL compared to 
sham animals.
Culture activation of HSC rapidly decreases PPAR gamma  expression at 3 and 7 days in culture Figure 2
Culture activation of HSC rapidly decreases PPAR gamma 
expression at 3 and 7 days in culture. 15dPGJ2 treatment for 
18 h to 7 day cultured HSC restores PPAR gamma expres-
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and TZD) rendered some of known biological effects via
PPAR gamma independent manner [6]. This raises a ques-
tion as to whether PPAR gamma itself is a true effector
molecule for the previously observed effects of PPAR
gamma ligands on HSC.
Special Effects of PPAR Gamma on HSC 
Activation
To demonstrate the effects of PPAR gamma, per se, Galli
et al. [2] transfected cultured activated human HSC with a
PPAR gamma expression vector. In this study, PDGF-stim-
ulated proliferation of HSC was decreased with expressed
PPAR gamma without ligand treatment. They further
reported the inhibition of TGF beta 1-induced human
alpha 2(I) procollagen promoter activity by transduced
PPAR gamma. Our recent transfection results suggest that
cultured activated HSC are depleted of PPAR gamma but
not its endogenous ligands (unpublished data), raising an
interesting question as to why these ligands are not driv-
ing PPAR gamma expression in these cells. We further
tested the effect of adenoviral-mediated expression of
PPAR gamma on activated HSC. By normalizing PPAR
gamma expression in this manner in culture-activated
HSC, activation markers such as TGF beta 1 and alpha 1(I)
procollagen genes were clearly suppressed and the mor-
phology of activated HSC was reverted toward the more
quiescent phenotype [7].
Conclusions
These findings from various laboratories demonstrate that
activation of HSC is associated with depletion of PPAR
gamma. Expression of PPAR gamma or addition of its lig-
ands reverts characteristic biochemical and morphologi-
cal changes of HSC activation suggesting the importance
of PPAR gamma in the maintenance of the quiescent HSC
phenotype.
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